Clinical trial
Growth Hormone Therapy in Osteogenesis Imperfecta
NCT00001305 · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), NIH · Completed
Key facts
| NCT number | NCT00001305 |
|---|---|
| Title | Growth Hormone Therapy in Osteogenesis Imperfecta |
| Official title | Studies of Growth Deficiency and Growth Hormone Treatment in Children With Osteogenesis Imperfecta Types III and IV |
| Lead sponsor | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), NIH |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Osteogenesis Imperfecta |
| Intervention type | Drug |
| Interventions | Humatrope |
| Enrollment | 42 |
| Start date | Nov 5, 1991 |
| Primary completion | May 19, 2017 |
| Completion | May 19, 2017 |
| First posted | Nov 4, 1999 |
| Last update posted | Jan 29, 2019 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: